MINNEAPOLIS, Feb. 26, 2020 /PRNewswire/ --Pingpong may hold promise as a possible form of physical therapy for Parkinson's disease. People with Parkinson's who participated in a pingpong exercise program once a week for six months showed improvement in their Parkinson's symptoms, according to a preliminary study released today that will be presented at the American Academy of Neurology's 72nd Annual Meeting in Toronto, Canada, April 25 to May 1, 2020.

Parkinson's disease is a movement disorder in which a chemical in the brain called dopamine is gradually reduced. This process results in slowly worsening symptoms that include tremor, stiff limbs, slowed movements, impaired posture, walking problems, poor balance and speech changes.

"Pingpong, which is also called table tennis, is a form of aerobic exercise that has been shown in the general population to improve hand-eye coordination, sharpen reflexes, and stimulate the brain," said study author Ken-ichi Inoue, M.D., of Fukuoka University in Fukuoka, Japan. "We wanted to examine if people with Parkinson's disease would see similar benefits that may in turn reduce some of their symptoms."

The study involved 12 people with an average age of 73 with mild to moderate Parkinson's disease. The people had been diagnosed with Parkinson's for an average of seven years.

The people were tested at the start of the study to see which symptoms they had and how severe the symptoms were.

Participants then played pingpong once a week for six months. During each weekly five-hour session, they performed stretching exercises followed by table tennis exercises with instruction from an experienced table tennis player. The program was developed specifically for Parkinson's disease patients by experienced table tennis players from the department of Sports Science of Fukuoka University.

Parkinson's symptoms were evaluated again after three months and at the end of the study.

The study found that at both three months and six months, study participants experienced significant improvements in speech, handwriting, getting dressed, getting out of bed and walking. For example, it took participants an average of more than two attempts to get out of bed at the beginning of the study compared to an average of one attempt at the end of the study.

Study participants also experienced significant improvements in facial expression, posture, rigidity, slowness of movement and hand tremors. For example, for neck muscle rigidity, researchers assessed symptoms and scored each participant on a scale of zero to four with a score of one representing minimal rigidity, two representing mild rigidity, three representing moderate rigidity and four representing severe rigidity. The average score for all participants at the start of the study was three compared to an average score of two at the end of the study.

Two participants experienced side effects. One person developed a backache and another person fell.

"While this study is small, the results are encouraging because they show pingpong, a relatively inexpensive form of therapy, may improve some symptoms of Parkinson's disease," said Inoue. "A much larger study is now being planned to confirm these findings."

The main limitation of the study was that the participants were not compared to a control group of people with Parkinson's disease who did not play pingpong. Another limitation was that a single specialist assessed the patients.

Learn more about Parkinson's disease at BrainandLife.org, home of the American Academy of Neurology's free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on Facebook, Twitter and Instagram.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with more than 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Follow this link:
Study Finds Picking up a Pingpong Paddle May Benefit People with Parkinson's - Southernminn.com

This study has articulated the Global Neurology Software Market with a detailed view of the Global Neurology Software industry including Global production sales, Global revenue, and CAGR. The report delivers core insights regarding the Neurology Software Market report with an in-depth study of market size, country-level market size, region, segmentation market growth, market share, sales analysis, value chain optimization, market players, the competitive landscape, recent developments, product launches, strategic market growth analysis, trade regulations, opportunities analysis, technological innovations, and area marketplace expanding. Moreover, it critically focuses on the application by analyzing the growth rate and consumption of every individual application.

Key vendor/manufacturers in the market:

The major players covered in Neurology Software are: Epic, Brainlab, healthfusion, Athenahealth, Practice Fusion, Nextgen, Bizmatics, Greenway Health, Allscripts, Kareo, Advanced Data Systems, NueMD, etc.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4162760

The Neurology Software Market report majorly offers an understanding about the major drivers, challenges, restraints, competitive landscape, increasing trends, market dynamics, market size, and market share, development status along with government policy, investment opportunities, and supply chains. It categorizes and analyze the segments regarding type, region, and application. This research report offers an aerial view of the Global Neurology Software Market including market share, price, revenue, growth rate, production by type.

The Global Neurology Software Market landscape and leading manufacturers offers competitive landscape and market development status including the overview of every individual market players. Furthermore, it offers productive data of vendors including the profile, specifications of product, applications, annual performance in the industry, sales, revenue, investments, acquisitions and mergers, market size, market share, and more.

The report also understand the export and import, production, and consumption of every particular region holding highest market share, market size, or CAGR. Furthermore, it provides a an potential insights regarding Porters Five Forces including substitutes, potential entrants, buyers, industry competitors, and suppliers with genuine information for understanding the Global Neurology Software Market.

Browse the complete report @ https://www.orbisresearch.com/reports/index/global-neurology-software-market-2020-by-company-regions-type-and-application-forecast-to-2025

Global Neurology Software Market By Type:

By Type, Neurology Software market has been segmented into Advanced Neurology EMR Software, Other, etc.

Global Neurology Software Market By Application:

By Application, Neurology Software has been segmented into Hospitals, College & Research Institutes, Other, etc.

Report covers detailed study about the gross margin, production, revenue, the price of the Global Neurology Software Market regarding different regions covered in particular section. It majorly focuses on manufacturing analysis including about the raw materials, cost structure, process, operations, and manufacturing cost strategies. The report introduces the industrial chain analysis, downstream buyers, and raw material sources along with the accurate insights of market dynamics. The Neurology Software Market reports delivers the knowledge about market competition between vendors through regional segmentation of markets in terms of revenue generation potential, business opportunities, demand & supply.

The report concludes with the coverage of data of big companies with information about their sales data, upcoming innovations and development, revenue margins, investments, business models, strategies, and business estimations.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4162760

Major Table of Contents

1 Neurology Software Market Overview2 Company Profiles3 Market Competition, by Players4 Market Size by Regions5 North America Neurology Software Revenue by CountriesContinued

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us: Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read the original here:
Global Neurology Software Market Drivers, Key Players, Regions, Application and Forecast to 2020-2025 - Nyse Nasdaq Live

Infants spontaneous and voluntary movements mirror the developmental integrity of brain networks since they require coordinated activation of multiple sites in the central nervous system. Accordingly, early detection of infants with atypical motor development holds promise for recognizing those infants who are at risk for a wide range of neurodevelopmental disorders.

Previously, novel wearable technology has shown promise for offering efficient, scalable, and automated methods for movement assessment in adults. Now, scientists from the University of Helsinki have developed a smart jumpsuit or a garment that accurately measures the spontaneous and voluntary movement of infants from the age of five months.

Sampsa Vanhatalo, professor of clinical neurophysiology at the University of Helsinki, said, The smart jumpsuit provides us with the first opportunity to quantify infants spontaneous and voluntary movements outside the laboratory. The child can be sent back home with the suit for the rest of the day. The next day, it will be returned to the hospital, where the results will then be processed.

The new analysis method quantifies infant motility as reliably as a human being would be able to do by viewing a video recording. After the measurement, the infants actual movements and physical positions will be known to the second, after which computational measures can be applied to the data.

This is a revolutionary step forward. The measurements provide a tool to detect the precise variation in motility from the age of five months, something which smart medical clothes have not been able to do until now.

The jumpsuit can detect abnormalities in the neurological development of infants at an early stage. Hence, it enables new support.

According to Leena Haataja, professor of pediatric neurology, developmental disorders in todays pressure-dominated world pose a considerable risk that can lead to learning difficulties and obstacles in the competition for education and jobs. Furthermore, they are a risk factor associated with exclusion from contemporary society.

Haataja said, The early identification of developmental disorders and support for infants everyday functional capacity in interaction with the family and the growth environment constitute a significant factor on the level of individuals, families, and society.

Haataja noted, The early identification of developmental disorders and support for infants everyday functional capacity in interaction with the family and the growth environment constitute a significant factor on the level of individuals, families, and society.

Smart jumpsuit can be used for the objective measurement of how various therapies and treatments affect childrens development.

The study is published in the Scientific Reports journal.

Read more here:
A smart jumpsuit that accurately measures the infants movement and development - Tech Explorist

When it comes to eating healthy, we're always on the hunt for lesser-known powerhouse veggies to incorporate into our diets. We asked neurologist and mbg Collective member David Perlmutter, M.D., what food he wants us all to eat in 2020, and he answered with a resounding (and fairly surprising) vegetable.

"We've known for a long time that broccoli is good food for us," Perlmutter said in an Instagram post. "It helps out the body's antioxidant function; it helps us reduce inflammation; it helps with detoxification."

But he's not pushing regular old broccoli. Rather, Perlmutter wants us to be eating broccoli sprouts.

Broccoli sprouts, at their most basic, are just what they sound like: an immature version of the cruciferous vegetable we all know and love. What makes them different and packs their power is a higher concentration of the necessary components to boost the production of sulforaphane.

In studies, sulforaphane has been linked to fighting against certain carcinogens, and it may support heart health and brain recovery as well. Researchers have also found it can support gut health, rounding out a pretty solid set of benefits that you may be able to attribute to these little sprouts.

Read the original:
The One Food A Neurologist Wants You To Eat (That You May Not Know) - mindbodygreen.com

This transcript has been edited for clarity.

Dear colleagues, I'm Christoph Diener, a neurologist from the University of Duisburg-Essen in Germany, here to discuss five interesting studies published in November 2019.

There are a number of registry studies indicating that low vitamin D3 levels are, perhaps, a risk factor in multiple sclerosis. In a publication in Neurology, investigators behind the SOLAR study reported results in 229 patients with relapsing-remitting multiple sclerosis treated with interferon-beta-1a. Patients were then randomized to receive either 14,000 units of vitamin D3 per day or placebo.

The primary endpointno evidence of disease activity at week 48was achieved by 35% in both treatment groups. Although there was no benefit to vitamin D3 overall, a subgroup analysis did show a tendency toward fewer new lesions on MRI imaging with vitamin D3.

A study published in The New England Journal of Medicine addressed the very important question of what is the best treatment for patients with status epilepticus who initially do not respond to benzodiazepines. Investigators randomized patients to receive levetiracetam (145 patients), fosphenytoin (118), or valproate (121).

The primary endpoint of absence of clinically evident seizures and improvement in the level of consciousness by 60 minutes after the start of drug infusion was achieved in 45%-47% of patients across the three treatments. There was no difference in efficacy. In terms of adverse events, there was a higher, but statistically insignificant, number of patients with hypotension and need for intubation in the fosphenytoin group, and a slightly higher mortality in the levetiracetam group.

Also published in The New England Journal of Medicine were results from the Treat Stroke to Target study. Investigators addressed the question of how low should the LDL cholesterol be in secondary stroke prevention after ischemic stroke or transient ischemic attack. They recruited 2860 patients and randomized them to two target groups: an LDL of < 70 mg/dL or an LDL between 90 and 110 mg/dL. Patients were followed for a median of 3.5 years.

The primary endpoint of major cardiovascular events or deaths from cardiovascular causes was reached in 8.5% in the lower-target group, who achieved an LDL of 65 mg/dL, and in 10.9% in the higher-target group, who achieved an LDL of 96 mg/dL. This translates to a hazard ratio of 0.78, representing a significant 22% risk reduction (P = .04).

The ACHIEVE II Study investigated the oral calcitonin gene-related peptide receptor antagonist ubrogepant versus placebo for the treatment of acute migraine attacks. Investigators recruited 1686 patients (90% female) who received ubrogepant at 25 or 50 mg or placebo.

The primary endpoint of being pain-free 2 hours after taking the medication was achieved by approximately 21% of the patients receiving ubrogepant at either dose, compared with 14% of the placebo group. There were very few side effects with ubrogepant outside of a little bit of nausea and dizziness.

However, this study was unable to answer the most important question of whether this new drug is equivalent in efficacy to sumatriptan. The other important question is whether this drug can be used in people who have contraindications for triptans, which, unfortunately, this study also could not answer.

Published in The Lancet, the CRASH-3 study investigated the possible benefit of tranexamic acid in acute brain injury with intracranial bleeding. Tranexamic acid, unfortunately, was not effective in spontaneous intracerebral haemorrhage. The current study recruited more than 12,000 patients who were randomized to receive tranexamic acid or placebo within 3 hours of brain injury. Participants had to have a Glasgow Coma Scale score of 12 or less and an intracranial bleed.

The death rate was 18.5% for tranexamic acid versus 19.8% for placebo, which translates to a 6% risk reduction that almost reached statistical significance. There was a statistically significant benefit if patients with very severe head injury were excluded. Here the risk reduction was 11% and was significant.

Tranexamic acid is obviously an option for people with traumatic intracranial haemorrhage. It's cheap, it's safe, and it did not lead to an increased risk for vascular occlusive disease.

Ladies and gentlemen, I'm Christoph Diener from the University of Duisburg-Essen. Thank you very much for listening about these five interesting studies from November 2019.

Dr Diener is an expert in the treatment of stroke and headache, and chairs the German Headache Consortium and the German Stroke Data Bank.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more:
LDL and Stroke Prevention: How Low to Go - Medscape

In the study, 85% (99/116) of children with life-threatening autoimmune conditions had complete or near complete recovery after biomarker was spotted and they were subsequently given appropriate treatment

A group of life-threatening neurological conditions affecting children have been linked to an antibody which points to potential treatment, according to an observational multicentre study involving 535 children with central nervous system (CNS) demyelinating disorders and encephalitis, published in The Lancet Neurology journal.

The findings suggest that the myelin oligodendrocyte glycoprotein (MOG) antibody is associated with a wider range of life-threatening autoimmune conditions than previously thought, including neuromyelitis optica spectrum disorders and encephalitis, which cause severe neurological (brain and nervous system) symptoms such as vision loss, muscle weakness, and loss of coordination and speech.

Because this group of CNS disorders can mimic similar conditions like multiple sclerosis (MS), they are difficult to diagnose correctly. Until around 10 years ago, patients with these demyelinating diseases were considered to have atypical forms of MS, and the prognosis and best treatment options were unknown. Over the last 10 years, multiple studies have shown that several demyelinating diseases (including optic neuritis, myelitis, and acute disseminated encephalomyelitis [ADEM]) associate with the MOG-antibody biomarker, and patients affected by this group of diseases frequently improve with immunotherapy. However, the best treatment approach and long-term outcome remain unknown. Now, this new study suggests that testing for the biomarker could speed accurate diagnosis and help identify the appropriate treatment for some of these disorders.

In the study, 85% (99/116) children who tested positive for MOG antibodies and given appropriate treatment had complete or near complete recovery, but 15% (17) experienced moderate to severe disease-related deficits not caused by the treatment (eg, cognitive impairment, epilepsy, vision loss), and one died from their disease.

"The diagnosis of many of these patients especially those with encephalitis would have been missed if it were not for the prospective design our study," says Dr Thais Armangue from the Sant Joan de Deu Children's Hospital, University of Barcelona, in Spain who co-led the research. "Identifying these patients is important because most of the children who tested positive for MOG antibodies responded to treatment with immunotherapy." [1]

Co-lead author Professor Josep Dalmau from the University of Barcelona explains, "Demyelinating diseases in children can be very difficult to distinguish because they present with similar symptoms and imaging features. Correct and early diagnosis allows for treatment with immunosuppressants, rather than the treatments specifically used in MS that are not effective in most of these diseases. Moreover, it is important to differentiate between those diseases that do not require chronic treatment and others in which prolonged immunotherapy is needed to improve long-term outcomes." [1]

MOG antibodies damage the protective covering (myelin sheath) that surrounds nerve fibres in the brain, optic nerves, and spinal cord, so messages cannot pass along these nerves effectively, causing symptoms such as vision loss, muscle weakness, and pain. Many children may only experience one MOG antibody disease event, and have no further symptoms. However, some children may be at risk of further relapses months, sometimes years, later.

Although there is increasing recognition of MOG-antibody associated syndromes in children, the full range of diseases associated with MOG antibodies remains unknown.

To provide more evidence, researchers conducted a prospective study of children (median age 6 years) with suspected demyelinating syndromes (239 children) and encephalitis other than ADEM (296) attending 40 hospitals across Spain between June 1, 2013, and December 31, 2018. Participants who tested positive for MOG antibodies were assessed for clinical features, response to treatment (ie, number of relapses), and outcomes over a median follow-up of 42 months.

In total, 116 (22%) of 535 children were found to be positive for MOG antibodies, including 94 (39%) with demyelinating syndromes and 22 (7%) with autoimmune encephalitis. Importantly, 24% (28/116) of these children had syndromes not previously associated with MOG antibodies.

Among the 64 patients with autoimmune encephalitis, MOG antibodies were the most frequent biomarkers--more common than all other neuronal antibodies combined (22 [34%] vs 21 [33%])--suggesting that MOG antibody testing should be conducted when diagnosing children with suspected encephalitis after excluding infectious causes, particularly as these patients often respond to treatment with immunotherapy.

The findings also suggest that younger children with MOG-antibody associated syndromes tend to present with clinical features of ADEM (which is an inflammatory condition that mainly affects the brain), whilst older children are more likely to have signs of optic neuritis (eg, loss of vision, pain in the eye) or myelitis (eg, back pain, weakness in both legs).

During follow-up, 33 (28%) of 116 patients positive for MOG antibody disease had relapses. Most of these patients (99/116, 85%) recovered well. However, 17 (15%) experienced disease-related moderate to severe deficits, and one died due to their disease.

"Despite advances in diagnostic testing for encephalitis, up to half of cases have no clear cause. Our findings reveal that the spectrum of MOG antibody disease is broader than previously thought and includes autoimmune encephalitis as well as multiple demyelinating syndromes", says co-author Dr Gemma Olive-Cirera from the Sant Joan de Deu Children's Hospital, University of Barcelona, Spain. "In light of our findings, current classifications and terminology of MOG antibody-associated syndromes should be updated." [1]

The authors note several limitations, including that this was not a registry-based study, and therefore could not assess the incidence or prevalence of MOG antibody-associated syndromes, and that the follow-up was short, which could result in the frequency of relapses being underestimated.

Writing in a linked Comment, Dr Romain Marignier from the Hpital Neurologique Pierre Wertheimer, France (who was not involved in the study) describes the research as "a milestone in the understanding of MOG antibody-associated syndromes", and writes: "In view of the very broad clinical spectrum now associated with MOG autoimmunity, the next challenge will be to identify the optimal therapeutic strategy for each clinical presentation. This objective is closely connected to a better understanding of the pathogenic role of MOG antibodies, and the need for early, robust, and specific prognostic factors of relapse and disability."

Go here to read the rest:
The Lancet Neurology: Discovery could speed diagnosis and treatment of children with life-threatening neurological diseases - Science Codex

CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive, a multimedia platform dedicated to providing health care professionals treating neurological diseases with direct access to expert-driven, practice-changing news and insights in neurology, announces the addition of the Consortium of Multiple Sclerosis Centers (CMSC) to its Strategic Alliance Partnership (SAP) program.

We are proud to be working with the CMSC, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of NeurologyLive. CMSC works to improve the lives of all who have been affected by MS by bringing together a society of MS medical professionals.

CMSC is an organization of multiple sclerosis health care professionals who strive to improve the lives of those affected by multiple sclerosis (MS). With over 250 member centers in the United States and Canada, CMSC represents over 12,000 health care professionals worldwide who provide care for more than 500,000 individuals with MS and their families.

NeurologyLive embraces a model of education and outreach that is consistent with the mission of the CMSC: a team approach, said June Halper, MSN, APN-C, CEO of CMSC. The target audience includes a constellation of professionals and supportive organizations allowing the CMSCs message to be heard loud and clear. We are grateful for this partnership.

The NeurologyLive SAP program is constantly building a community of health plans, advocacy groups, medical associations and medical institutions to foster collaboration and an open exchange of information for the ultimate benefit of patients and their families and to improve patient care. As part of this joint effort, NeurologyLive and CMSC will share exclusive content with each other.

For more information about the NeurologyLive SAP program, click here. For more information about CMSC, click here.

About NeurologyLive

A multimedia platform for health care professionals treating neurological diseases, NeurologyLive delivers direct access to practice-changing news and expert insights directly from top medical conferences and researchers to improve the lives of patients with neurological diseases such as dementia and Alzheimer disease, epilepsy, headache and migraine, movement disorders, multiple sclerosis, neuromuscular diseases, sleep disorders and stroke. The NeurologyLive platform offers an in-depth look at the hundreds of new treatments in development with ever-expanding mechanisms of action, all during an unprecedented time of growing demand for neurology expertise. The NeurologyLive platform also connects visitors with the most up-to-date clinical trial results, Food and Drug Administration approvals, practice-changing research and expert insights. NeurologyLive is a brand of MJH Life Sciences, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

About Consortium of Multiple Sclerosis Centers (CMSC)

The Consortium of Multiple Sclerosis Centers (CMSC), is the leading educational, training, and networking organization for MS healthcare professionals, researchers and professionals in training. The CMSC mission is to promote high quality MS care through educational programming and accreditation including live and online events, research grants, technical journals and papers, and targeted advocacy efforts. The CMSC member network includes more than 12,000 international healthcare clinicians and scientists committed to MS care as well as more than 60 Veterans Administration MS Programs and 250 MS Centers in the US, Canada, and Europe. The 34th CMSC Annual Meeting, the largest gathering of MS healthcare professionals in North America, will take place May 27 30, 2020, in Orlando, FL. For more information visit: http://www.mscare.org. Follow CMSC on Twitter: @mscare and Facebook: http://www.facebook.com/CMSCmscare.

Read more:
NeurologyLive Adds the Consortium of Multiple Sclerosis Centers to Its Strategic Alliance Partnership Program - Business Wire

HOUSTON The death of a 5-year-old boy is being investigated as a possible bacterial meningitis case.

The Montgomery County Public Health District said the case was reported to them on New Years Eve.

Myles Cheathams family told KHOU 11 the boy fell ill on Dec. 28 and died two days later at Texas Childrens Hospital in The Woodlands. MCPHD officials said Myles family was given preventative treatment and there is no risk to the general public.

Dr. Hana El Sahly, associate professor of molecular biology, microbiology and infectious diseases at Baylor College of Medicine, said not everyone who comes in contact with the bacteria that causes meningitis will get sick.

For most people the acquisition goes unnoticed," Dr. El Sahly said.

That is why its so important to be aware of your body. Dr. El Sahly said bacteria that can cause infections like meningitis are everywhere and are very serious.

People with weaker immune systems are more likely to develop meningitis.

Its usually coming in contact with someone who has the bacteria in their upper respiratory tract and transmission to another person, she said.

Dr. El Sahly said the disease causes inflammation of the lining of the brain. She said getting sick can happen really quickly.

Symptoms to be on the lookout for include fever, headaches, stiffness of the neck, nausea and vomiting.

Neurologic findings like fever and all of a sudden an inability to move or having particular neurologic dysfunction," Dr. El Sahly said.

She urges people to keep track how theyre feeling especially when something seems out of the ordinary.

Fever on its own that resolves or responds to certain medications should not be alarming, Dr. El Sahly said.

She added hygiene is crucial and so is keeping up with vaccines because they can help lower the risk of developing infectious diseases like meningitis.

RELATED: Vaccine group announces creation of Ebola vaccine stockpile

RELATED: Michigan teen on ventilator after mosquito bite, mom says

Continue reading here:
What is bacterial meningitis and how do you protect yourself? - KHOU.com

We are pleased to welcome the board-certified neurologists of Knoxville Neurology Specialists to Covenant Health and Fort Sanders Regional Medical Center.

Knoxville Neurology Specialists is the practice of Timothy Braden, MD; Darrell Thomas, MD; Joel Torres, MD; and Gregory Wheatley, MD. Together, the physicians bring more than 60 years of combined medical experience treating diseases of the brain, spine and nervous system. Almost all conditions can be treated within their practice, as they subspecialize in different areas of neurology, including adult neurology, epilepsy, and neuromuscular diseases.

Learn more about the neurologists below.

Board Certified in Neurology

Neurology,Wake Forest Baptist Medical Center

University of Tennessee, Memphis

Board Certified in Neurology

Electrodiagnosis and Neuromuscular Diseases,University of Alabama

Neurology,Bowman Gray School of Medicine

University of Tennessee, MemphisKnoxville Neurology

Board Certified in Neurology

Neuromuscular Medicine,Wake Forest Baptist Medical Center

Neurology,Wake Forest Baptist Medical Center

East Tennessee State UniversityJames H. Quillen College of Medicine

Board Certified in Neurology

Epilepsy,University of Alabama School of Medicine

Electrophysiology,Mayo Clinic

Neurology,West Virginia University Hospital

University of Tennessee, Memphis

Knoxville Neurology Specialistsat Fort Sanders Regional Medical Center501 20th Street, Suite 505Knoxville, TN 37916

For an appointment with one of our neurologists or for more information about the medical services provided at Knoxville Neurology Specialists, call(865) 546-0157.

Here are directions to help you easily find our office.

Tags for this post:Covenant Health, Covenant Medical Group, Darrell Thomas, Dr. Darrell Thomas, Dr. Gregory Wheatley, Dr. Joel Torres, Dr. Timothy Braden, fort sanders regional medical center, Gregory Wheatley, Joel Torres, Knoxville Neurologist, Knoxville Neurology, Knoxville Neurology Specialists, Timothy Braden

Continue reading here:
Knoxville Neurology Specialists Joins Covenant Health

Please wait while the PDF is generating...

There was a problem generating your PDF. Please try again later.

St. Luke's is the leading provider of primary and specialty care for your entire family in the greater Lehigh Valley and Warren County, New Jersey.

St. Luke's specialty care providers play an important role in your family's health and well-being and are committed to providing you with quality and compassionate care. New patients are welcome.

After-Hours Calls and Emergencies:If you have a health concern that arises at night or over the weekend, please call our office's main number. The answering service will contact the physician on-call. If you believe any delay in medical attention could result in a life-threatening situation, please go immediately to the nearest emergency room for treatment and notify our office as soon as you are able. For life-threatening emergencies, please use 911.

Practice Addresses

true940.6884-75.2207Reset the MapWJu9QBTrAmRuDzJ8Iz62

St. Luke's Neurology Associates

1417 Eighth Avenue

Bethlehem,PA18018

St. Luke's Neurology Associates

St. Luke's Anderson Campus Medical Office Building

1700 St. Luke's Boulevard

Suite 300

Easton,PA18045

St. Luke's Neurology Associates

240 Cetronia Road

Suite 210

Allentown,PA18104

St. Luke's Neurology Associates

St. Luke's Bone & Joint Institute

1534 Park Avenue

Suite 330

Quakertown,PA18951

St. Luke's Neurology Associates

59 Roseberry Street

Phillipsburg,NJ08865

St. Luke's Neurology Associates

St. Luke's Miners Campus

360 West Ruddle Street

Coaldale,PA18218

St. Luke's Neurology Associates

St. Luke's Tamaqua Medical Center

120 Pine Street

Suite 106

Tamaqua,PA18252

St. Luke's Neurology Associates

St. Luke's Health Center - Macungie

2550 Route 100

Suite 230

Macungie,PA18062

St. Luke's Neurology Associates

3 Parkinsons Road

East Stroudsburg,PA18301

St. Luke's Neurology Associates

St. Luke's Center Valley Health Center

5445 Lanark Road

Suite 202

Center Valley,PA18034

St. Luke's Neurology Associates

525 Iron Street

Suite B

Lehighton,PA18235

St. Luke's Neurology Associates

Inpatient Neurology

1021 Park Avenue

Quakertown,PA18951

St. Luke's Neurology Associates

Inpatient Neurology

801 Ostrum Street

Bethlehem,PA18015

St. Luke's Neurology Associates

1107 Eaton Avenue

Suite F

Bethlehem,PA18018

St. Luke's Neurology Associates

240 Cetronia Road

Suite 210

Allentown,PA18104

To view all providers in this practice CLICK HERE.

Physical Medicine & Rehabilitation

Read the original here:
St. Luke s Neurology Associates - St. Luke's University ...

Message from the Department of Neurology

Welcome to the Neurosciences Institute at Albany Medical Center. We are proud to be the regions first choice for the diagnosis, treatment and care of disorders and diseases affecting the brain, spine and peripheral nervous system. As members of the Albany Medical College faculty, our providers specialize in the diagnosis and treatment of specific diseases, and many are national leaders defining new standards of care.

Our multidisciplinary team of expert neurologists, neurosurgeons and physiatrists treats everyone from newborns to adults with disorders including brain tumors, epilepsy, Parkinsons disease, stroke, aneurysms, Alzheimers disease, muscular dystrophy, multiple sclerosis, ALS (Lou Gehrigs disease) and neuropathic pain.

Our achievements are many.

In addition to earning the Get With The Guidelines Gold Plus Quality Achievement Award from the American Stroke Association, Albany Medical Center is the only hospital in the region, and one of only 13 statewide, to be certified by both the New York State Department of Health as a Stroke Center and by the Joint Commission as a Primary Stroke Center with the organizations Gold Seal of Approval as an accredited institution with an advanced certification in stroke care.Along with programs at other prestigious institutions including the Cleveland Clinic and Johns Hopkins, Albany Meds Epilepsy and Human Brain Mapping Program is designated Level 4, the highest distinction authorized by the National Association of Epilepsy Centers.

Our Alzheimers Center was named a Center of Excellence for Alzheimers disease as designated by the New York State Department of Health.

And, our neuromuscular program is the only one in the area recognized by the Muscular Dystrophy Association.

With our comprehensive array of services and team of experts, Albany Medical Center is uniquely qualified to bring world-class care to people of all ages with neurological disorders.

See the rest here:
Neurology - Albany Medical Center

Pamela M. Rist

From the Division of Preventive Medicine, Department of Medicine (P.M. Rist, J.E.B., P.M Ridker), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Neurology (C.S.K.), Emory University, Atlanta, GA; Institute of Public Health (T.K.), CharitUniversittsmedizin, Berlin, Germany; and Division of Women's Health, Department of Medicine (K.M.R.), Brigham and Women's Hospital, Boston, MA.

Julie E. Buring

From the Division of Preventive Medicine, Department of Medicine (P.M. Rist, J.E.B., P.M Ridker), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Neurology (C.S.K.), Emory University, Atlanta, GA; Institute of Public Health (T.K.), CharitUniversittsmedizin, Berlin, Germany; and Division of Women's Health, Department of Medicine (K.M.R.), Brigham and Women's Hospital, Boston, MA.

Paul M Ridker

From the Division of Preventive Medicine, Department of Medicine (P.M. Rist, J.E.B., P.M Ridker), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Neurology (C.S.K.), Emory University, Atlanta, GA; Institute of Public Health (T.K.), CharitUniversittsmedizin, Berlin, Germany; and Division of Women's Health, Department of Medicine (K.M.R.), Brigham and Women's Hospital, Boston, MA.

Carlos S. Kase

From the Division of Preventive Medicine, Department of Medicine (P.M. Rist, J.E.B., P.M Ridker), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Neurology (C.S.K.), Emory University, Atlanta, GA; Institute of Public Health (T.K.), CharitUniversittsmedizin, Berlin, Germany; and Division of Women's Health, Department of Medicine (K.M.R.), Brigham and Women's Hospital, Boston, MA.

Tobias Kurth

From the Division of Preventive Medicine, Department of Medicine (P.M. Rist, J.E.B., P.M Ridker), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Neurology (C.S.K.), Emory University, Atlanta, GA; Institute of Public Health (T.K.), CharitUniversittsmedizin, Berlin, Germany; and Division of Women's Health, Department of Medicine (K.M.R.), Brigham and Women's Hospital, Boston, MA.

Kathryn M. Rexrode

From the Division of Preventive Medicine, Department of Medicine (P.M. Rist, J.E.B., P.M Ridker), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Neurology (C.S.K.), Emory University, Atlanta, GA; Institute of Public Health (T.K.), CharitUniversittsmedizin, Berlin, Germany; and Division of Women's Health, Department of Medicine (K.M.R.), Brigham and Women's Hospital, Boston, MA.

More:
Lipid levels and the risk of hemorrhagic ... - n.neurology.org

Tamara Pringsheim

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Michael S. Okun

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Kirsten Mller-Vahl

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Davide Martino

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Joseph Jankovic

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Andrea E. Cavanna

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Douglas W. Woods

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Michael Robinson

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Elizabeth Jarvie

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Veit Roessner

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Maryam Oskoui

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Yolanda Holler-Managan

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

John Piacentini

From the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences (T.P., D.M.), Cumming School of Medicine, University of Calgary, Alberta, Canada; Departments of Neurology and Neurosurgery (M.S.O.), Fixel Center for Neurological Diseases, University of Florida, Gainesville; Department of Psychiatry, Social Psychiatry, and Psychotherapy (K.M.-V.), Hannover Medical School, Germany; Department of Neurology (J.J.), Baylor College of Medicine, Houston, TX; Department of Neuropsychiatry (A.E.C.), BSMHFT, University of Birmingham and Aston University, UK; Department of Psychology (D.W.W.), Marquette University, Milwaukee, WI; Massachusetts Chapter (M.R.), Tourette Association of America, Bayside, NY; Waisman Center (E.J.), University Center for Excellence in Developmental Disabilities, University of Wisconsin, Madison; Technische Universitaet Dresden (V.R.), Germany; Departments of Pediatric and Neurology/Neurosurgery (M.O.), McGill University, Montral, Canada; Department of Pediatrics (Neurology) (Y.H.-M.), Northwestern University Feinberg School of Medicine, Chicago, IL; and Department of Psychiatry and Biobehavioral Sciences (J.P.), Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles.

Go here to see the original:
Practice guideline recommendations ... - n.neurology.org

About Conference

We welcome you and appreciate your participation at the26thEuropean Neurology Congress, which will be held during August 06-08,2018 in Madrid, Spain and will be organized around the theme of "Harnessing the understanding and advancement in Neurology and Neuroscience

Neurology Congress 2018will be operated by world class experts in the field of neurology and Neuroscience, International symposiums, B2B meetings, workshops will also be organised to discuss the specific topics in the field ofNeurologylike Neuro Genesis, Neurophysiology, Neurological Disorders, Neuro Muscular Disorders, Neuro Infecticious Diseases, Neuropathology and Neuroplasticity. The conference is aimed in to identify the genetic determinants of common disorders to understand the mechanisms underlying human cognition.Neurogenetic Disordersare common among developed and developing countries. Genetic disorders and congenital abnormalities occur in around 2-5% of live births accounting for approximately 30% of pediatric hospital admissions in many places in the world. Neurogenetic conditions are generally chronic, long-term and incurable. In Netherlands approximately 10% of patients with neurological conditions have a single mutated gene as the basis for their disease. Furthermore, when polygenic inheritance is considered that is, the interplay between multiple genes and environment, a much larger proportion of neurological diseases are included.Dementiais strongly linked with age, and the Netherlands and other European countries have an increasingly ageing population. Currently 16% of the European population is over 65, with this figure expected to reach 25% by 2030. In the Netherlands it has been estimated that dementia alone costs the economy 17 billion a year.

Student Poster Competition is organized at Conference, to encourage students and recent graduates to present their original research which will be later published in the OMICS International Journals. All accepted abstracts will be presented at the poster sessions during the conference. OMICS International provides an opportunity to present E-Poster for all the students who cannot attend the conference at 99$ with abstract published in the website with DOI number Live Streaming is a value added service offering to speaker at OMICS International Conference.

Business networking is an avenue for vendors to have network and B2B meetings with Top scientists and colleagues and with an effective low cost marketing method for developing sales and opportunities and contacts, based on referrals and introductions either face-to-face at meetings and gatherings, or by other contact methods such as Telephone, E mail, Digital and Increasingly social and business networking websites.

Why to attend?

NeurologyCongress 2018 will bring together experts like Neuroscientists, Clinicians, Neurogeneticst, Neurologists, Psychiatrists, Medical practitioners, Care specialists, academic professionals and students from all over the world to share an interest in the genetic pathways underlyingneurological disorders, techniques to identify those genetic pathways, and the use of genetics and genomics as tools to develop therapeutics.

The aim of the conference is to provide a platform to academicians and practitioners from multiple disciplines to debate and deliberate on social change that is encompassed by innovation and technology.

Target Audience

Neurologists and Directors

Physicians

Neuroscientists

Specialists

Researchers

Health care professionals

Professors

Industrial Experts

Neurosurgeons

Psychiatrist

Nutritional Scientists

Lecturers and Students from Academia

Students from Academia in the research of Neurology

Track 01: Neurology

Neurologydeals with the treatment and diagnosis of all categories of conditions and disease involving the peripheral and central nervous system including their coverings, blood-vessels and all effector tissue, such as muscle.Neurologistsmay also be involved in clinical trials,clinical researchand basic or translational research.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 02 :Neurophysiology

The study of nature and origin of the brain which also concerns with the functioning ofthe nervous system, often usingelectrophysiologicalor molecular biological tools. This is the subspecialty of both the physiology andNeuroscienceas different regions of brain constitute signals to different parts of the body. This topic could give detailed description about the revolutionized anatomy of nervous system, the motor response control system, thought processing and memory management system. Discussions can also be made inneuromuscular physiology, neural mechanisms of higher nervous activity and contemporary problems of Neuroscience can also be conferred. It features board investigations in the Neuropathology and interdisciplinary departments ofNeuro ophthalmology, Neuro otology.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 03 :Child Neurology

Child neurologyrefers to a branch of medicine that deals with the management and diagnosis of neurological conditions inneonates,children, infants andadolescents. The discipline of child neurology encompasses diseases and disorders of thebrain, peripheral nervous system,spinal cord, autonomic nervous system and blood vessels that affects individuals in these age groups.

If child has problems that involve the nervous system, pediatric neurologist has the specialistknowledge to assess,diagnose, training and treat the child. The conditions deal with bypediatric neurologist'svary considerably, from relatively disorders such as cerebral palsy or migraine through to more complex and rare conditions such asneurodegenerative disordersor metabolic disease.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 04 :Central Nervous System

TheCentral Nervous Systemhas hundred billions of neurons which work by tolerating, engendering and transmitting electrochemical driving forces.Neurobiologymanages useful humanneuroanatomyandneurophysiologyof cerebrum, spinal rope, white and dim issue, cerebrospinal liquid, synaptic and circuit elements.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 05 :Neuromuscular Disorders

Neuromuscular disordersare disorders of the nerves that control the voluntary muscles. One of the causes is the immune system disorder and genetic. More than 2 million people in the United States are affected by such form ofneuromusculardiseases and about 30% of them are under the age18.Diagnosisincludes NCV test, biochemical, genetic test, a multi-step process like muscle biopsyetc. The motive of this session is to understand the origin of Musculardystrophy, Lambert-Eaton syndrome andneuromuscular junction disorder. Further there will be an interactive conversation on Hyper reflexia, Spasticyand its prevention.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 06 :Neurosurgery

Neurosurgeryrefers to the medical specialty dedicated to the diagnosis, prevention, treatment, and rehabilitation of disorders that affects our nervous system i.e spinal cord, brain, peripheral nerves, and extra-cranial cerebrovascular system. Developed in the first half of the twentieth centuryneurosurgeryhas witnessed till date exponential advances in intensive care, technology and sophisticated non-invasive procedures. This has undoubtedly have widened the scope of neurosurgical practice. Paediatric neurosurgery, Functional neurosurgery, Neurovascular surgery, Traumatology, Neuro-oncology,Skull-base surgery,Spinal surgeryare the different categories of neurosurgery

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 07:Neuroradiology and Neuro Imaging

Neuroimagingis the visual function of brain and nervous system. Throughneuroimagingdiagnosisof current status and progression of neurodegenerative, psychiatric, intracranial disease is possible. Neuroimaging includes various techniques such as PET,MRI, and CT for diagnosis.

Biomarkercan be any substance which is introduced into organisms as an indicator for detecting,screening, diagnosing, monitoring organ function. Biomarker indicates whether there is any disease or healthy state. Use of biomarkers is increasing day by day indrugs development. A biomarkers should be easy to measure easily modifiable, cost effective for treatment and should be consistent with gender.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 08:Clinical Neurology andNeuropsychiatry

Neuropsychiatry is the branch of Neurology that deals with neural andmental disorders attributable to diseases of the nervous system. It preceded current disciplines of neurology and psychiatry, which had common. Psychiatry and neurology subsequently split aparts and are typical practiced separately. Clinical neuropsychology is a subspecialty ofclinical psychologythat specialises in assessment and treatment of patients with brain disease or injury. Epilepsy is the third common neurological disorder in the Europe after stroke, andAlzheimers disease.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 09:Neuropharmocology

Neuropharmacology is the study of drugs that affect cellular functions in the neural mechanisms andnervous system, through which they influence behavior. Molecularneuropharmacologyinvolve the study of neurons and their neurochemical interactions with the overall motive of developing new drugs that have beneficial effects onnervous system.This session also includes to group think the alteration in psychiatric diseases,neuromodulationand the recent Drug development in the field of Neuro-immunological disorders.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 10:NursingCare in Neurology

Neurological Nursing is very challenging nursing specialty dealing withnursing diagnosis, assessment and management of many neural disorders for which nurses provides patient care. This includes brain injuries, trauma,stroke, seizures, infections, headaches and aneurysms as well as a host of other neurological complexities. Over an estimated half billion people worldwide are affected by neurological diseases and disorders. 9 million people in the United Kingdom alone suffer from neurological conditions.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 11 :Neurotherapeutics, Diagnostics and Case Studies

In order to accelerate the discoveries of novel diagnostic therapy, gathering of neurology researchers is encouraged in order to discuss on neural disorder and treatment,Neurogenesis, Nerve injury and repair andheadache, and last but not the least some new therapeutics evolved for neurological disorders. An estimated 72,120 new cases of primarybrain tumorsare expected to be diagnosed in 2012, that includes both malignant andnon-malignantbrain tumors. Basing on prevalence of diseases, Conference focuses on advances in neurological treatment.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 13 :Spine Disorders

Spine disordersoccurs in individuals irrespective of their age -spina bifida in infants to spinal stenosis in the elderly. Many types ofspinal disordersare seen. The increase inspinal disordershas been met with a leap in advancements in the diagnostic techniques.Endoscopic spine , X rays, MRI, CT and DEA are some of the widely used tool s in diagnosingspinal disorders.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 14 :Neuroplasticity

Neuroplasticity also known asbrainplasticity. It is an umbrella term that encompasses both non-synaptic plasticity and synaptic plasticity. It refers to change in synapses and neural pathways due to changes in environment, neural processes, thinking, behavior and emotions. The motive of this session is to understand the neuro-plasticity, advances in theNeurite remodelingand How to increaseNeural-Connections.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Tracks 15 :Neural Engineering

Brainengineering orNeural engineeringcan be used to understand, replace,repair, enhance and otherwise exploit the properties of the neural systemsandNeuro-computing are the study of neurons function in terms of information processing property of structures that make up the nervous system. The current researches in the field of neural engineering include: neural networking, Neural imaging and Biomoleculartherapies inneuralregeneration, Biological neural networking, Neurorobotics, Neuro hydrodynamics and clinical treatment, Engineering strategies for repair.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Track 16:Neuropathology

Neuropathologyis the study of diseases related to nervous system tissue, usually in the form of either small whole autopsies or surgical biopsies. Neuropathologyis a subspecialty of anatomic pathology, neurology, andneurosurgery. Diseases with diverse the etiologic and genetic features have very similar clinical and pathologic characteristics. From theNeuropathologicalpoint of view, types and incidences of neuropathologic changes and the diseases that they produce correlate with the major periods of life.

RelatedNeurology Conferences|Neurology Congress|Neuroscience Events|Meetings on Neurology

Neurology Congress 2017 welcomes attendees, presenters, and exhibitors from all over the world to Madrid, Spain. We are delighted to invite you all to attend and register for the26th European Neurology Congress which is going to be held during August 06-08, 2018 in Madrid, Spain.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at theNeurology Congress 2017,where you will be sure to have a meaningful experience with scholars from around the world. All members of the Neurology Congress 2017 organizing committee look forward to meeting you in Madrid, Spain.

For more details please visit-http://www.neurologyconference.com/europe

Importance and Scope:

European Neurology Congressis a unique forum to bring together worldwide distinguished academics in the field of neuroscience and neurology, Brain researchers, public health professionals, scientists, academic scientists, industry researchers, scholars to exchange about state of the art research and technologies.

The aim of this conference is to stimulate new ideas for treatment that will be beneficial across the spectrum of Neuroscience.

Conferences, National symposiums, and Workshops provide a dedicated forum for the advancement, execution and exchange of information about Neuroscience and its allied areas.

Why Madrid?

Madrid is the most populous city and thecapital ofSpain with a metropolitan area of about 3.2million Inhabitants. There are about 15 Universities in and around Spain which are working in the field of Neurological disorder. Around 1000 neurologist, psychiatrist and neurosurgeons are working exclusively on Neurological disorder in Spain. Along with professional services, media companies are concentrated in Spain and the media distribution industry is Spains second most competitive sector.

National Alliance provided the fund of $650 million to fuel the research on mental illness. NARSAD Young Investigator Grant provides $30,000 per year on research in Neural and behavior disorders such as schizophrenia, mood disorders, anxiety disorders, or child and adolescent mental illnesses. Brain tumor research receives less than 1% (0.7%) of national cancer research spending in the UK.

Conference Highlights:

Why attend???

International Conference on Neurology and Therapeutics is a unique forum to bring together worldwide distinguished academics in the field of neuroscience and neurology, Brain researchers, public health professionals, scientists, academic scientists, industry researchers, scholars to exchange about state of the art research and technologies.

The aim of this conference is stimulate new ideas for treatment that will be beneficial across the spectrum of Brain disorders.

A Unique Opportunity for Advertisers and Sponsors at this International event:

http://neurologyconference.com/europe/sponsors.php

Major Associations around the Globe

Around 20 associations of Neurology are there in Spain

A few associations of Neuroscience in Spain are:

Target Audience:

Directors, neurologist, neurosurgeons, psychiatrist, head of department, Professors, and Students from Academia in the research of Neuroscience.

Target Audience:

Academia 60%

Industry 30%

Others 10%

Around 500 top universities globally working in the field of Neuroscience

There are around 200 universities in Spain which are working in the field of Neurology

There are about 15 Universities in and around Madrid which are working in the field of Neurology

Hospitals Associated with Neuroscience Research

Read more from the original source:
Neurology | Neurology Conference | Neurosurgery Conference ...

Peripheral Nerve Disorders includes other areas of care:

- Acute Inflammatory Demyelinating Polyradiculoneuropathy

- Alcoholic Neuropathy

- Alcoholic Polyneuropathy

- Anterior Ischemic Optic Neuropathy

- Auditory Neuropathy

- Autonomic Disorders

- Autonomic Dysreflexia

- Autonomic Neuropathy

- Carcinomatous Polyneuropathy

- Carotid Sinus Syncope

- Chronic Demyelinating Neuropathy With IgM Monoclonal Gammapathy

- Chronic Inflammatory Demyelinating Polyneuropathy

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy

- Congenital Neuropathy With Arthrogryposis Multiplex Congenita

- Congenital Sensory Neuropathy With Neurotrophic Keratitis

- Demyelinating Polyneuropathy

- Diabetic Neuropathy

- Diabetic Polyneuropathy

- Hand Neuropathy

- Hereditary Neuropathy With Liability to Pressure Palsies

- Hereditary Sensory and Autonomic Neuropathy, Type I

- Infantile Refsum Disease

- Inflammatory and Toxic Neuropathy

- Inflammatory Neuropathies

- Leber Hereditary Optic Neuropathy

- Metabolic Neuropathy

- Motor and Sensory Neuropathy With Sensorineural Hearing Loss, Bouldin Type

- Motor Neuropathy

- Motor Neuropathy, Peripheral With Dysautonomia

- Multifocal Motor Neuropathy

- Multifocal Motor Neuropathy With Conduction Block

- Neuropathy, Distal Hereditary Motor

- Neuropathy, Distal Hereditary Motor, Jerash Type

- Neuropathy, Distal Hereditary Motor, Type III

- Neuropathy, Distal Hereditary Motor, Type VIIa

- Neuropathy, Hereditary Motor and Sensory, Lom Type

- Neuropathy, Hereditary Motor and Sensory, Okinawa Type

- Neuropathy, Hereditary Sensory, Radicular

- Neuropathy, Hereditary Sensory, Type I

- Neuropathy, Hereditary Sensory, Type II

- Neuropathy, Hereditary Sensory, Type IV

- Neuropathy, Motor & Sensory

- Optic Neuropathy

- Peripheral Neuropathy

- Peroneal Muscular Atrophy

- Polyneuropathy

- Polyradiculoneuropathy

- Pudenal Neuropathy

- Reflex Sympathetic Dystrophy

- Retrobulbar Neuropathy

- Sensory Neuropathy With Spastic Paraplegia

- Spinal Bulbar Motor Neuropathy

- Spinocerebellar Ataxia With Axonal Neuropathy, Type 2

- Spinocerebellar Ataxia, Autosomal Recessive, With Axonal Neuropathy

- Toxic Polyneuropathy Due to Acrylamide

- Ulnar Neuropathy

- Vascular Neuropathy

See the original post here:
Dr. Frederick Jennart Jr, DO - Warner Robins, GA ...

A group of scientists from the Research Center of Neurology and Skoltech showed that human working memory can be tweaked using non-invasive magnetic stimulation of the brain. Also, they discovered that the effect of magnetic stimulation weakens as the brain works on a cognitive task under stimulation. The results of their study were published in the journal Brain Sciences.

Working memory (WM) stores and processes the information we need for daily use. The WM mechanisms get activated when, for example, we memorize a phone number until we find a scrap of paper or a smartphone to write it down. WM disorders are a frequent occurrence in many nervous system diseases, whereas in healthy people, the WM capacity is associated with an individuals learning ability and general intelligence level.

The transcranial magnetic stimulation (TMS) is regarded as one of the promising non-pharmacological WM enhancement methods leveraging the effect of the alternating magnetic field which painlessly penetrates through the scalp and skull bones, with an electric field forming in the cortex. As TMS can influence the mechanisms of neuroplasticity, it is used as a therapeutic method for various nervous system diseases. The TMS effects are known to depend both on the stimulation parameters and the brain activity during stimulation. Combining TMS with concurrent cognitive activity has evolved into a cognitive enhancement technique for patients with Alzheimers disease. However, data are still lacking on how exactly the brain activity influences the TMS efficiency.

The researchers compared the effects of TMS on WM when stimulation was applied with and without a cognitive load. The WM performance was evaluated before and after a 20-minute stimulation session. The stimulation area was selected based on the individual brain activation pattern which formed during a WM-engaging task. The results suggest that WM does not respond to any stimulation other than TMS with no cognitive load.

The results of our research lead us to conclude that cognitive activity can reduce rather than increase the TMS efficiency. This should be borne in mind when developing new stimulation protocols for cognitive enhancement in both healthy volunteers and patients suffering from various nervous system diseases, says Natalya Suponeva, Head of Department of Neurorehabilitation and Physiotherapy at the Research Center of Neurology and Associate Member of RAS.

Maxim Fedorov, Director of the Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE), is inspired by the research outcomes and the ensuing opportunities: The results attest to the efficiency of interdisciplinary research in biomedicine and cognitive sciences, benefiting from advanced data processing methods. We at CDISE have much interest in collaborating with the Research Center of Neurology and studying WM mechanisms for a number of reasons. First, this would be an exciting experience and a good opportunity to apply some of the findings in practice in the short term (better memory is what many of us need). Second, modern biomedical research tools open up broad horizons for data and AI scientists. Data are abundant but sometimes too noisy and the data samples are often heterogeneous. Generally speaking, we are faced with non-trivial tasks that prompt ideas for new research targets in our field. Third, many ideas in Big Data and AI, such as neural networks, were born out of research into the human higher nervous activity. And this is very interesting. Currently, we are busy working on many projects at the crossroads of neuroscience, simulation and Big Data. Personally, I believe that man is as boundless as the Universe, and we are just beginning to understand how interesting we are and how much potential we have. I am convinced that we have a lot of unexpected discoveries ahead of us. We strongly hope that our collaboration with the Research Center of Neurology will be a continued success.

Currently, the study is moving forward with a larger number of healthy volunteers in order to validate the recent findings and evaluate the long-term effect of TMS on WM performance.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
New Research Shows That Human Working Memory can be Tweaked With Non-Invasive Magnetic Stimulation - Technology Networks

KITCHENER A former Kitchener neurologist charged with sexually assaulting dozens of women has been released on bail, the Crown confirmed on Monday.

Jeffrey Sloka, 51, got bail on Friday and is now under house arrest.

Sloka, who had an office at Grand River Hospital and privileges at St. Mary's General Hospital, is charged with sexually assaulting 68 women.

He was initially charged last September with sexually assaulting 34 female patients under his care from January 2010 to February 2017. More charges were laid in December and still more in February of this year. None of the allegations have been proven.

Sloka had been in protective custody at Maplehurst jail in Milton after being assaulted there in September.

Fear of the COVID-19 pandemic spreading to Ontario jails is leading to an increase in the number of people being released from custody. It is unclear whether that move has anything to do with Sloka's release.

Under his bail conditions, Sloka must live with his surety, stay in the residence unless he's with his surety or for medical, dental or legal appointments, notify police of any change in address, possess no weapons and have no contact with the alleged victims.

He is set to return to court on June 1.

Before any charges were laid, Sloka faced non-criminal disciplinary action by the College of Physicians and Surgeons of Ontario.

He agreed last April to never practise medicine again after his licence was revoked.

The agreement confirmed Sloka was the subject of a further 22 investigations.

Sloka pleaded no contest at the hearing held in Toronto by the College of Physicians.

"We take the safety and quality of care for our patients very seriously," Grand River Hospital said in a previous statement, "and the alleged actions of Mr. Sloka do not reflect the values, standards, beliefs or behaviour of our staff and physicians."

gpaul@therecord.com

Twitter: @GPaulRecord

gpaul@therecord.com

Twitter: @GPaulRecord

Continued here:
UPDATE: Charged with sexually assaulting 68 women, former Kitchener neurologist goes from jail to house arrest - TheRecord.com

St. Anthony Hospital is set to once again expand its Midtown campus with construction of a two-story neurology clinic.

The 17,438-square-foot building is set to be built on vacant land at the southwest corner of NW 9 and Shartel adjacent to a collection of modern homes known as SoSA. That acronym stands for south of St. Anthony.

Plans show space for six physicians on the first floor with additional doctors' space to be leased on the second floor.

The project will include 26 parking spots for patients with staff parking to be provided in the hospital garage across the street.

Over the past dozen years, St. Anthony has invested $220 million rebuilding its campus and redeveloping Midtown.

Dr. Salman Zubair, who is leading the latest project, said the clinic represents an expansion of the hospital's neurology services. Construction is set to start later this year.

We will have new equipment, new technology and special expertise in neurology that will be provided to patients, Zubair said.

The designs by ADG, led by architect Betsy Brunsteter, cite material inspiration from surrounding modern homes and the nearby Lift apartments. The plans include the possibility of a second-floor balcony.

It's a great site with a great focal point, Brunsteter said. We're taking advantage of that with the design.

See more here:
New neurology clinic planned at St. Anthony in Midtown Oklahoma City - NewsOK.com

Patients are benefiting from a new hospital ward opening up in Aberdeen.

Neurosurgery patients suffering from acute illness, such as brain injuries, have been sharing a space at Aberdeen Royal Infirmary with neurology patients with chronic or life-limiting conditions.

The two groups require different types of care and NHS Grampian has now launched a dedicated space for people admitted for neurology care.

Describing the layout before the change, consultant neurosurgeon Anastasios Giamouriadis said: We would have a patient who is recovering from surgery for a brain tumour and were expecting improvement nursed in a bed next to a patient with progressive motor neurone disease (MND) that we are trying to delay the worsening and deterioration of the neurological condition.

As far as the staff are concerned these patients have different needs. Whereby neurosurgery patients need less and less support neurology patients need more support over time.

Caroline McIntosh, who is the senior charge nurse for the new neurology ward also known as Ward 204 said: Its an opportunity to enhance the already excellent care we are giving patients.

Weve been working to specialities in one unit and doing it exceptionally well with lots of positive feedback.

Claire McNab, senior charge nurse for the neurosurgery ward known as Ward 205 said: This is an evolution of the service we already offer to further improve the care we provide.

The way you nurse both sets of patients is very different.

Neurosurgical patients come in either for a listed operative procedure or with an acute illness where they receive surgery and then either go on to receive oncology services or rehab.

They are with us for their neuro treatment be it brain surgery, spinal or something similar and then they tend to go on for specialist care in different areas.

With neurology patients, because they usually have a life-limiting or chronic illness, like MS or MND, the management of that is quite different.

Ward 204 will have 10 beds and Ward 205 will have 17 beds maintaining the same number as before the change.

Caroline said she hoped having two dedicated wards will help attract graduate nurses in both neurology and neurosurgery.

She added: It will provide a better environment for learning for newly qualified nurses and we will hopefully capture their interest in one area and can go on to further their education and training from there.

Hopefully over the next five years we will see benefits and staff vacancies will drop as a result and it will help us recruit new people and also retain them.

Although we are going to be two separate wards it will still be a neuroscience floor and we will work together for the best of the patients.

On the same floor is the neurophysiology department and we also have the planned investigation unit.

Read more from the original source:
New Aberdeen hospital ward gives neurology patients the care they need - Aberdeen Evening Express

MINNEAPOLIS, Feb. 28, 2020 /PRNewswire/ --Children and teens with epilepsy who were treated with pharmaceutical cannabidiol (CBD) had much better seizure control than those who were treated with artisanal CBD, according to a preliminary study to be presented at the American Academy of Neurology's 72nd Annual Meeting in Toronto, Canada, April 25 to May 1, 2020.

CBD is a cannabis component that relieves stress and anxiety and has anti-seizure properties. It does not produce a "high" like another cannabis component called tetrahydrocannabinol (THC). Pharmaceutical CBD for epilepsy does not have THC. It is FDA approved for use in two severe forms of childhood epilepsy, Dravet syndrome and Lennox-Gastaut syndrome, which do not respond well to other medications. Artisanal CBD is manufactured using varying techniques and contains variable amounts of CBD and THC.

"The use of medical cannabis to treat various medical conditions has grown in recent years. While not always legal, artisanal CBD has been available longer, so some people have been using it to treat epilepsy for years," said study author Nathan T. Cohen, M.D., of Children's National Hospital in Washington D.C., and a member of the American Academy of Neurology. "They may want to reconsider because our research indicates that pharmaceutical CBD may indeed be more effective than artisanal CBD."

For the study, researchers reviewed the medical charts of 31 children and teens with an average age of 10 who were followed for an average age of one year. All had some form of epilepsy including 32% with Lennox-Gastaut syndrome and 6% with Dravet syndrome. Of the group, 22 were taking pharmaceutical CBD and nine were taking artisanal CBD. Researchers recorded medication doses, levels of CBD in the blood, seizure history and reduction in seizures with medication and side effects.

Those taking artisanal CBD had an average level of CBD in the blood of 31 nanograms per milliliter (ng/mL) compared to 124 ng/mL for those taking pharmaceutical CBD.

Researchers found children and teens taking artisanal CBD had a 70% increase in seizures during the study. Those taking prescription CBD had a 39% reduction in seizures.

However, 11 participants reported side effects. All were taking pharmaceutical CBD. Side effects included sleepiness, low appetite, nausea and diarrhea. Six of those participants stopped taking pharmaceutical CBD due to side effects.

"The difference in seizure control is dramatic and is definitely of concern since many people continue to use artisanal CBD," said Cohen. "However, a limitation of our study is that it was small. More research is needed to see if similar results are found in larger groups of people."

Another limitation of the study was that it was a look back at medical records. It did not involve participants who were given either pharmaceutical or artisanal CBD and then followed over time.

Learn more about epilepsy at BrainandLife.org, home of the American Academy of Neurology's free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on Facebook, Twitter and Instagram.

The American Academy of Neurology is the world's largest association of neurologists and neuroscience professionals, with more than 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, concussion, Parkinson's disease and epilepsy.

For more information about the American Academy of Neurology, visit AAN.com or find us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

Read this article:
Study Finds Artisanal CBD Not as Effective as Pharmaceutical CBD for Reducing Seizures - Southernminn.com